Page 2195 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 130 Acquired Disorders of Platelet Function 1943.e5

203. Furie B, Greene E, Furie BC: Syndrome of acquired factor X deficiency 229. Noris M, Remuzzi G: Uremic bleeding: closing the circle after 30 years
and systemic amyloidosis in vivo studies of the metabolic fate of factor of controversies? Blood 94:2569, 1999.
X. N Engl J Med 297:81, 1977. 230. Remuzzi G, Perico N, Zoja C, et al: Role of endothelium-derived nitric
204. Meyer K, Williams EC: Fibrinolysis and acquired alpha-2 plasmin oxide in the bleeding tendency of uremia. J Clin Invest 86:1768, 1990.
inhibitor deficiency in amyloidosis. Am J Med 79:394, 1985. 231. Noris M, Todeschini M, Zappella S, et al: 17b-estradiol corrects
205. Kasturi J, Saraya AK: Platelet functions in dysproteinaemia. Acta hemostasis in uremic rats by limiting vascular expression of nitric oxide
Haematol 59:104, 1978. synthases. Am J Physiol Renal Physiol 279:F626–F635, 2000.
206. Djunic I, Elezovic I, Ilic V, et al: The effect of paraprotein on platelet 232. Zoja C, Vigano G, Bergamelli A, et al: Prolonged bleeding time and
aggregation. J Clin Lab Anal 28:141, 2014. increased vascular prostacyclin in rats with chronic renal failure: effects
207. Vigliano EM, Horowitz HI: Bleeding syndrome in a patient with IgA of conjugated estrogens. J Lab Clin Med 112:380, 1988.
myeloma: interaction of protein and connective tissue. Blood 29:823, 233. Sloand JA, Sloand EM: Studies on platelet membrane glycoproteins and
1967. platelet function during hemodialysis. J Am Soc Nephrol 8:799, 1997.
208. DiMinno G, Coraggio F, Cerbone AM, et al: A myeloma paraprotein 234. Himmelfarb J, Holbrook D, McMonagle E, et al: Increased reticulated
with specificity for platelet glycoprotein IIIa in a patient with a fatal platelets in dialysis patients. Kidney Int 51:834, 1997.
bleeding disorder. J Clin Invest 77:157, 1986. 235. Plé H, Maltais M, Corduan A, et al: Alteration of the platelet transcrip-
209. Rinder MR, Richard RE, Rinder HM: Acquired von Willebrand’s tome in chronic kidney disease. Thromb Haemost 108:605, 2012.
disease: a concise review. Am J Hematol 54:139, 1997. 236. Gaspari F, Vigano G, Orisio S, et al: Aspirin prolongs bleeding time in
210. Perkins HA, MacKenzie MR, Fudenberg HH: Hemostatic defects in uremia by a mechanism distinct from platelet cyclooxygenase inhibi-
dysproteinemias. Blood 35:695, 1970. tion. J Clin Invest 79:1788, 1987.
211. Pogliani EM, Colombi M, Cofrancesco E, et al: Platelet dysfunction in 237. Eberst ME, Berkowitz LR: Hemostasis in renal disease: pathophysiology
acute megakaryoblastic leukemia. Acta Haematol 81:1, 1989. and management. Am J Med 96:168, 1994.
212. Hendrick AM, Shah S, Raich PC: Platelet dysfunction in acute mega- 238. Hellem AJ, Borchgrevink CF, Ames SB: The role of red cells in hae-
karyoblastic leukemia. Arch Pathol Lab Med 108:63, 1984. mostasis: the relation between haematocrit, bleeding time and platelet
213. Psaila B, Bussel JB, Frelinger AL, et al: Differences in platelet function adhesiveness. Br J Haematol 7:42, 1961.
in patients with acute myeloid leukemia and myelodysplasia compared 239. Fernandez F, Goudable C, Sie P, et al: Low haematocrit and prolonged
to equally thrombocytopenic patients with immune thrombocytopenia. bleeding time in uraemic patients: effect of red cell transfusions. Br J
J Thromb Haemost 9:2302, 2011. Haematol 59:139, 1985.
214. Lintula R, Rasi V, Ikkala E, et al: Platelet function in preleukaemia. 240. Blajchman MA, Bordin JO, Bardossy L, et al: The contribution of the
Scand J Haematol 26:65, 1981. haematocrit to thrombocytopenic bleeding in experimental animals. Br
215. Cortelazzo S, Viero P, D’Emilio A, et al: Platelet dysfunction in sple- J Haematol 86:347, 1994.
nectomized patients with hairy cell leukemia. Eur J Cancer Clin Oncol 241. Cases A, Escolar G, Reverter JC, et al: Recombinant human erythro-
22:935, 1986. poietin treatment improves platelet function in uremic patients. Kidney
216. Bellucci S, Huisse MG, Boval B, et al: Defective collagen-induced Int 42:668, 1992.
platelet activation in two patients with malignant haemopathies is 242. Sagripanti A, Barsotti G: Bleeding and thrombosis in chronic uremia.
related to a defect in the GPVI-coupled signalling pathway. Thromb Nephron 75:125, 1997.
Haemost 93:130, 2005. 243. Lutz J, Menke J, Sollinger D, et al: Haemostasis in chronic kidney
217. Raman V, Quillen K, Sloan JM: Acquired Glanzmann thrombasthenia disease. Nephrol Dial Transplant 29:29, 2014.
associated with Hodgkin lymphoma: rapid reversal of functional plate- 244. Violi F, Ferro D, Basili S, et al: Prognostic value of clotting and fibri-
let defect with ABVD (adriamycin/bleomycin/vinblastine/dacarbazine) nolytic systems in a follow-up of 165 liver cirrhotic patients. CALC
chemotherapy. Clin Lymphoma Myeloma Leuk 14:e51–e54, 2014. Group. Hepatology 22:96, 1995.
218. Frigeni M, Galli M: Childhood myelodysplastic syndrome associated 245. Violi F, Ferro D, Basili S, et al: Hyperfibrinolysis increases the risk
with an acquired Bernard-Soulier-like platelet dysfunction. Blood of gastrointestinal hemorrhage in patients with advanced cirrhosis.
124:2609, 2014. Hepatology 15:672, 1992.
219. Avvisati G, Tirindelli MC, Annibali O: Thrombocytopenia and hemor- 246. Sanchez-Roig MJ, Rivera J, Moraleda JM, et al: Quantitative defect
rhagic risk in cancer patients. Crit Rev Oncol Hematol 48:S13–S16, of glycoprotein Ib in severe cirrhotic patients. Am J Hematol 45:10,
2003. 1994.
220. Oudemans-van Straaten HM: Hemostasis and thrombosis in continu- 247. Violi F, Leo R, Basili S, et al: Association between prolonged bleed-
ous renal replacement treatment. Semin Thromb Hemost 41:91, 2015. ing time and gastrointestinal hemorrhage in 102 patients with
221. Salvati F, Liani M: Role of platelet surface receptor abnormalities in the liver cirrhosis: results of a retrospective study. Haematologica 79:61,
bleeding and thrombotic diathesis of uremic patients on hemodialysis 1994.
and peritoneal dialysis. Int J Artif Organs 24:131, 2001. 248. Stein SF, Harker LA: Kinetic and functional studies of platelets, fibrino-
222. Castillo R, Lozano T, Escolar G, et al: Defective platelet adhesion on gen, and plasminogen in patients with hepatic cirrhosis. J Lab Clin Med
vessel subendothelium in uremic patients. Blood 68:337, 1986. 99:217, 1982.
223. Gralnick HR, McKeown LP, Williams SB, et al: Plasma and platelet 249. Laffi G, Cominelli F, Ruggiero M, et al: Altered platelet function in
von Willebrand factor defects in uremia. Am J Med 85:806, 1988. cirrhosis of the liver: impairment of inositol lipid and arachidonic acid
224. Casonato A, Pontara E, Vertolli UP, et al: Plasma and platelet von Wil- metabolism in response to agonists. Hepatology 8:1620, 1988.
lebrand factor abnormalities in patients with uremia: lack of correlation 250. Kunihiro N, Kawai B, Sanjo A, et al: Platelet aggregation and coagula-
with uremic bleeding. Clin Appl Thromb Hemost 7:81, 2001. tion and fibrinolysis parameters in both portal and systemic circulations
225. Thekkedath UR, Chirananthavat T, Leypoldt JK, et al: Elevated in patients with cirrhosis and hepatocellular carcinoma. Hepatol Res
fibrinogen fragment levels in uremic plasma inhibit platelet func- 19:52, 2001.
tion and expression of glycoprotein IIb-IIIa. Am J Hematol 81:915, 251. Lisman T, Bongers TN, Adelmeijer J, et al: Elevated levels of von
2006. Willebrand Factor in cirrhosis support platelet adhesion despite reduced
226. Diaz-Ricart M, Estebanell E, Cases A, et al: Abnormal platelet cyto- functional capacity. Hepatology 44:53, 2006.
skeletal assembly in hemodialyzed patients results in deficient tyrosine 252. Mannucci PM, Canciani MT, Forza I, et al: Changes in health and
phosphorylation signaling. Kidney Int 57:1905, 2000. disease of the metalloprotease that cleaves von Willebrand factor. Blood
227. Horowitz HI, Cohen BD, Martinez P, et al: Defective ADP-induced 98:2730, 2001.
platelet factor 3 activation in uremia. Blood 30:331, 1967. 253. Reuken PA, Kussmann A, Kiehntopf M, et al: Imbalance of von Wil-
228. Horowitz HI, Stein IM, Cohen BD, et al: Further studies on the lebrand factor and its cleaving protease ADAMTS13 during systemic
platelet-inhibitory effect of guanidinosuccinic acid and its role in inflammation superimposed on advanced cirrhosis. Liver Int 35:37,
uremic bleeding. Am J Med 49:336, 1970. 2015.